Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-079 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuni...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding
Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuni...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding
Request for Information (RFI): Soliciting Input on the National Institutes of Allergy and Infectious Diseases (NIAID) New Innovator Awards (DP2 Clinical Trials Optional)
Notice NOT-AI-19-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 5, 2018 Category: Research Source Type: funding
What Contributes to the Success of Early Career Scientists? – A NIAID Look
At NIH, we are heavily invested in our workforce and in understanding the barriers they face. What characteristics do they share? How do they compete in the current hypercompetitive environment? When do they stop applying to NIH (drop out), even after receiving their first award?
Staff from the National Institute of Allergy and Infectious Diseases (NIAID) delve into these questions in a paper published recently in PLOS ONE , whose findings I’d like to highlight today. Here, Drs. Patricia Haggerty and Matthew Fenton looked at factors that may contribute to the success of early-career investigators and if these factors aff...
Source: NIH Extramural Nexus - October 31, 2018 Category: Research Authors: Mike Lauer Tags: blog Open Mike Uncategorized biomedical research workforce Biomedical Workforce Early Stage Investigators Funding data funding rate Source Type: funding
Fc-Dependent Mechanisms of Antibody-Mediated Killing (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-18-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 5, 2018 Category: Research Source Type: funding
Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-19-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R21 applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (A...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 5, 2018 Category: Research Source Type: funding
Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-923 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 17, 2018 Category: Research Source Type: funding
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)
Funding Opportunity PA-18-902 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 14, 2018 Category: Research Source Type: funding
Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional)
Funding Opportunity PAR-18-879 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support extramural investigator-initiated clinical research in collaboration and partnership with intramural investigators at the NIH Clinical Center in Bethesda, MD. This new FOA will leverage the resources (inpatient and outpatient) and assets of the NIH Clinical Center (e.g., scientific, clinical trial and expertise, nursing, beds, critical care services, ambulatory care services, laboratories, imaging, biostatistics, protocol development, regulatory guidance, clinical trials management and safety oversight) in a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 26, 2018 Category: Research Source Type: funding
Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-876 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 25, 2018 Category: Research Source Type: funding
Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-873 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infectio...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 24, 2018 Category: Research Source Type: funding
Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-872 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 24, 2018 Category: Research Source Type: funding
Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-860 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods. The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod s...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 19, 2018 Category: Research Source Type: funding
The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-784 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involve...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2018 Category: Research Source Type: funding
Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trials Not Allowed)
Funding Opportunity PAR-18-781 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Research areas supported by this FOA include: immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced imm...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 11, 2018 Category: Research Source Type: funding
